Trial · NCT07904871
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT07904871, Not applicable, Not yet recruiting, First Affiliated Hospital of Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Trials, record NCT07904871. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904871
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- NCT number
- NCT07904871
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 46 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Conditions
- Myelofibrosis, Primary Myelofibrosis (PMF), Secondary Myelofibrosis
- Interventions
- Peri-Transplant Gecacitinib
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1-Year GVHD-Free, Relapse-Free Survival (GRFS) | From transplantation (Day 0) to 12 months after transplantation | The proportion of participants alive at 1 year after allogeneic hematopoietic stem cell transplantation without any of the following events: grade III-IV acute graft-versus-host disease (GVHD), chronic GVHD requiring systemic immunosuppressive treatment, relapse or progression of myelofibrosis, or death from any cause. The first occurrence of any component event will be considered a GRFS event. Acute GVHD will be graded according to MAGIC criteria, and chronic GVHD will be assessed according to the 2014 NIH consensus criteria. |
| Secondary | Progression-Free Survival（PFS） | At 12 months after transplantation | PFS is defined as the time from transplantation to the first occurrence of myelofibrosis relapse or progression, or death from any cause. PFS probabilities will be estimated using the Kaplan-Meier method. |
| Secondary | Overall Survival（OS） | At 12 months after transplantation | OS is defined as the time from transplantation to death from any cause. Participants alive at the last follow-up will be censored. OS probabilities will be estimated using the Kaplan-Meier method. |
| Secondary | Cumulative Incidence of Grade II-IV Acute GVHD | From transplantation to Day +180 | Cumulative incidence of grade II-IV acute graft-versus-host disease assessed according to the MAGIC criteria. Death without prior acute GVHD will be treated as a competing event. |
| Secondary | Cumulative Incidence of Grade III-IV Acute GVHD | From transplantation to Day +180 | Cumulative incidence of grade III-IV acute graft-versus-host disease assessed according to the MAGIC criteria. Death without prior acute GVHD will be treated as a competing event. |
| Secondary | Cumulative Incidence of Moderate-to-Severe Chronic GVHD | At 12 months after transplantation | Cumulative incidence of moderate-to-severe chronic graft-versus-host disease assessed according to the 2014 NIH consensus criteria. Death without prior chronic GVHD will be treated as a competing event. |
| Secondary | Cumulative Incidence of Non-Relapse Mortality (NRM) | At 6 and 12 months after transplantation | Cumulative incidence of death without prior relapse or progression of myelofibrosis. Disease relapse or progression will be considered a competing event. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904871
GET https://conductscience.org/api/trials/v1/NCT07904871/registered